• Cataract/Anterior Segment, Comprehensive Ophthalmology, Retina/Vitreous

    A weekly roundup of ophthalmic news from around the web.

    Telemedicine screening can be cost effective in lower-income communities. While the use of telemedicine screening in ophthalmology has greatly increased over the last several years, particularly in underserved populations, the cost-effectiveness of these programs has not been widely studied. Researchers conducted a chart review of 2251 patients enrolled in the diabetic retinopathy (DR) telemedicine screening program at Montefiore Health System (Bronx, NY), 519 of whom were found to have DR. The cost-effectiveness model applied to the data yielded an estimated cost per quality-adjusted life year (QALY) of $57,778/QALY for DR and $35,471/QALY for all ophthalmic diseases detected, with an estimated total cost savings of $124,736. The cost per QALY fell well within the thresholds set, indicating that the telemedicine screening program was cost effective while providing benefits to an underserved population. Clinical Ophthalmology

    Higher-income countries see better outcomes after cataract surgery. A systematic review and meta-analysis evaluated global variations in post–cataract surgery outcomes, including visual acuity, based on country income. Thirty-five studies were included. Although there are limited data on postsurgical outcomes from low- and middle-income countries (LMICs) other than China and India, in general fewer patients in LMICs had postsurgical visual acuity ≥0.32 than patients in higher-income countries, and only about half the surgeries in LMICs resulted in a presenting VA ≥6/18. To improve these outcomes, the authors recommend that “actions to integrate and coordinate the continuous medical care for postoperative patients, development of standardized follow-up process, and financial support for the patients and health institutions should be implemented.” British Journal of Ophthalmology

    A treatment for night vision disturbances shows good efficacy in a phase 3 trial. Topline results from the phase 3, placebo-controlled LYNX-1 clinical trial, conducted in 145 patients with night vision disturbances, found that more patients who were randomized to Nyxol (0.75% phentolamine ophthalmic solution) had a gain of ≥15 letters in distance vision than patients randomized to placebo (13% vs 3% at day 8, respectively, and 21% vs 3% at day 15, respectively). No serious adverse events were reported. Full study results will be presented at upcoming medical meetings. Ocular Surgery News, ClinicalTrials.gov

    On the ONE Network

    Don’t miss last week’s roundup: AMD and poor cognition, need for more eye clinicians, tinnitus and glaucoma